2008ORBi (University of Liège)Requires access

Effect of a single 5 mg infusion of zoledronic acid on bone turnover markars vs. oral risedronate (5 mg/day) over 1 year in patients with glucocorticoid-induced osteoporosis

Philip N. Sambrook, J.-P. Devogelaer, Jean‐Yves Reginster, Kenneth G. Saag, C. Roux, Chak Sing Lau, P. Papanastasiou, Oliver Schönborn‐Kellenberger, K. Maylandt, T. Fashola, Peter G Mesenbrink, David M. Reid

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Medicine, Zoledronic acid, Osteoporosis, Glucocorticoid, Bone remodeling, Internal medicine, Rheumatology, Bone Density Conservation Agents

Related papers

Back to paper searchBrowse research topicsOriginal source
Effect of a single 5 mg infusion of zoledronic acid on bone turnover markars vs. oral risedronate (5 mg/day) over 1 year in patients with glucocorticoid-induced osteoporosis — Research Paper | ScholarLens